Exploratory pharmacokinetic study of Rikkunshito (TJ-43) in healthy volunteers.
- Conditions
- Healthy volunteers
- Registration Number
- JPRN-jRCT1080221759
- Lead Sponsor
- Tsumura & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 4
1)Subject body mass index (BMI) is between 18.5 and 25 kg/m2
2)Willing and able to provide written, signed informed consent
1) Subjects with a history of allergic reactions to drugs and food(s).
2) Female subjects who are pregnant, breastfeeding or planning to become pregnant.
3) Subjects who have participated in another clinical trial within 16 weeks prior to study drug administration.
4) Subjects who have had their blood drawn or donated > 400mL of blood within 12 weeks prior to study drug administration.
5) Subject with history of significant hepatic, cardiovascular or hematological disease.
6) Subjects with hepatic steatosis.
7) Subjects who can not give up smoking and drinking alcohol at a hospitalization time to the end of test.
8) Subject who can not stop using any medicine (e.g., antipsychotic, antifungal, antihypertensive, Kampo medicine, etc.) from 7 days prior to trial drug medication to that.
9) Use of supplements containing JP Atractylodes Lancea Rhizome, JP Ginseng,
JP Pinellia Tuber, JP Poria Sclerotium, JP Jujube, JP Citrus Unshiu Peel,
JP Glycyrrhiza, JP Ginger.(JP: The Japanese Pharmacopoeia)
10) Use of any agent within 7 days prior to study drug administration.
11) Subjects with abnormal clinical laboratory values inappropriate for the study in the opinion of the principal investigator/subinvestigator.
12) Subjects who are deemed ineligible for other reasons by the principal investigator/subinvestigator.
13) Subjects who have positive HCV antibody, HBs antigen, HIV antibody.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method